Sujal M. Patel Acquires 53,300 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel bought 53,300 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the transaction, the chief executive officer now owns 10,117,788 shares in the company, valued at $10,016,610.12. This trade represents a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Nautilus Biotechnology Stock Performance

Nautilus Biotechnology stock opened at $0.99 on Friday. The firm has a 50 day moving average price of $1.54 and a two-hundred day moving average price of $2.11. Nautilus Biotechnology, Inc. has a 52-week low of $0.93 and a 52-week high of $3.09. The firm has a market cap of $124.89 million, a price-to-earnings ratio of -1.77 and a beta of 1.25.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lowered shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and cut their price target for the stock from $2.25 to $1.75 in a report on Thursday, December 5th. Guggenheim set a $2.50 target price on Nautilus Biotechnology in a report on Friday, February 28th.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC grew its holdings in Nautilus Biotechnology by 171.4% during the 4th quarter. Citadel Advisors LLC now owns 220,220 shares of the company’s stock worth $370,000 after acquiring an additional 139,081 shares during the period. JPMorgan Chase & Co. grew its stake in Nautilus Biotechnology by 309.9% during the fourth quarter. JPMorgan Chase & Co. now owns 145,937 shares of the company’s stock worth $245,000 after purchasing an additional 110,334 shares during the period. Wexford Capital LP increased its holdings in Nautilus Biotechnology by 42.4% in the fourth quarter. Wexford Capital LP now owns 325,239 shares of the company’s stock worth $546,000 after purchasing an additional 96,889 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Nautilus Biotechnology by 61.7% in the fourth quarter. Renaissance Technologies LLC now owns 250,221 shares of the company’s stock valued at $420,000 after buying an additional 95,521 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Nautilus Biotechnology by 11.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company’s stock worth $1,294,000 after buying an additional 78,367 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.